Vaxart, Inc. Total Liabilities and Equity
Vaxart, Inc. (VXRT) had Total Liabilities and Equity of $165.19 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $165.19M.
- 2026-03-31: Liabilities and Equity $180.06M.
- 2025-12-31: Liabilities and Equity $186.08M.
- 2025-09-30: Liabilities and Equity $208.99M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $165.19M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $180.06M S-1 · filed 2026-05-08 | |
| 2025-12-31 | $186.08M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $208.99M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $164.09M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $158.56M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $166.39M S-1 · filed 2026-05-08 | |
| 2024-09-30 | $166.67M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $113.75M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $88.67M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $91.83M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $105.64M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $122.65M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $129.85M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $153.85M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $175.31M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $181.45M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $200.38M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $221.17M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $241.14M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $228.84M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $205.87M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $152.58M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $154.71M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $64.19M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $52.56M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $37.03M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $42.70M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $37.25M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $36.31M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $35.23M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $40.64M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $47.76M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $56.54M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $4.52M 10-K · filed 2019-02-06 | $32.60M 10-Q · filed 2018-02-06 |
| 2017-09-30 | $34.70M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $40.10M 10-Q · filed 2018-02-06 | |
| 2017-03-31 | $46.70M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $56.50M 10-Q · filed 2017-02-06 | |
| 2016-09-30 | $63.10M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $72.70M 10-K · filed 2017-09-01 | |
| 2016-03-31 | $61.90M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $64.20M 10-Q · filed 2016-02-08 | |
| 2015-09-30 | $71.00M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $79.40M 10-K · filed 2016-09-13 | |
| 2015-03-31 | $88.80M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $93.40M 10-Q · filed 2015-02-06 | |
| 2014-09-30 | $97.30M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $114.00M 10-K · filed 2015-09-11 | |
| 2014-03-31 | $120.50M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $82.70M 10-Q · filed 2014-02-10 | |
| 2013-09-30 | $79.00M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $85.80M 10-K · filed 2014-09-30 | $84.30M 10-K · filed 2013-09-27 |
| 2013-03-31 | $94.84M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $96.18M 10-Q · filed 2013-02-11 | |
| 2012-09-30 | $66.51M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $69.30M 10-K · filed 2013-09-27 | $92.95M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $95.24M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $97.97M 10-Q · filed 2012-11-08 | |
| 2011-09-24 | $104.05M 10-Q · filed 2011-11-02 | |
| 2011-06-25 | $105.34M 10-Q · filed 2011-08-03 | |
| 2010-12-25 | $113.87M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |